Personalis, Inc. (PSNL): Price and Financial Metrics


Personalis, Inc. (PSNL): $4.58

0.47 (+11.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PSNL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PSNL POWR Grades


  • Sentiment is the dimension where PSNL ranks best; there it ranks ahead of 70.26% of US stocks.
  • PSNL's strongest trending metric is Momentum; it's been moving down over the last 179 days.
  • PSNL's current lowest rank is in the Quality metric (where it is better than 9.87% of US stocks).

PSNL Stock Summary

  • PSNL's went public 2.78 years ago, making it older than merely 8.17% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 518.16%, Personalis Inc's debt growth rate surpasses 97.26% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PSNL comes in at -43.99% -- higher than that of only 9.71% of stocks in our set.
  • Stocks that are quantitatively similar to PSNL, based on their financial statements, market capitalization, and price volatility, are SDGR, TTNP, ENTX, HTBX, and CLSN.
  • Visit PSNL's SEC page to see the company's official filings. To visit the company's web site, go to www.personalis.com.

PSNL Valuation Summary

  • In comparison to the median Healthcare stock, PSNL's price/sales ratio is 0.44% higher, now standing at 11.4.
  • PSNL's price/sales ratio has moved down 5.6 over the prior 27 months.
  • Over the past 27 months, PSNL's EV/EBIT ratio has gone up 25.1.

Below are key valuation metrics over time for PSNL.

Stock Date P/S P/B P/E EV/EBIT
PSNL 2021-08-31 11.4 2.8 -18.7 -17.5
PSNL 2021-08-30 11.2 2.7 -18.4 -17.2
PSNL 2021-08-27 11.1 2.7 -18.2 -17.0
PSNL 2021-08-26 10.3 2.5 -16.9 -15.7
PSNL 2021-08-25 10.4 2.5 -17.2 -16.0
PSNL 2021-08-24 10.3 2.5 -17.0 -15.8

PSNL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PSNL has a Quality Grade of D, ranking ahead of 6.55% of graded US stocks.
  • PSNL's asset turnover comes in at 0.259 -- ranking 67th of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows PSNL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.259 0.327 -0.268
2021-03-31 0.311 0.292 -0.325
2020-12-31 0.398 0.256 -0.443
2020-09-30 0.436 0.269 -0.492
2020-06-30 0.482 0.283 -0.583
2020-03-31 0.426 0.315 -0.904

PSNL Price Target

For more insight on analysts targets of PSNL, see our PSNL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $33.57 Average Broker Recommendation 1.38 (Strong Buy)

PSNL Stock Price Chart Interactive Chart >

Price chart for PSNL

PSNL Price/Volume Stats

Current price $4.58 52-week high $28.47
Prev. close $4.11 52-week low $3.94
Day low $4.09 Volume 597,200
Day high $4.65 Avg. volume 474,262
50-day MA $6.34 Dividend yield N/A
200-day MA $13.15 Market Cap 208.15M

Personalis, Inc. (PSNL) Company Bio


Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.


PSNL Latest News Stream


Event/Time News Detail
Loading, please wait...

PSNL Latest Social Stream


Loading social stream, please wait...

View Full PSNL Social Stream

Latest PSNL News From Around the Web

Below are the latest news stories about Personalis Inc that investors may wish to consider to help them evaluate PSNL as an investment opportunity.

Personalis Inc's (PSNL) CEO John West on Q4 2021 Results - Earnings Call Transcript

Personalis, Inc. (PSNL) Q4 2021 Earnings Conference Call February 24, 2022 5:00 PM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Kevin DeGeeter – Oppenheimer Patrick Donnelly – Citi Stephanie Yan – Cowen...

SA Transcripts on Seeking Alpha | February 25, 2022

Exchange - Geode Capital Management LLC Has $10.99 Million Stake in Personalis, Inc

Geode Capital Management LLC grew its position in Personalis, Inc. by 5.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 571,369 shares of the company''s…

Business Mag | February 24, 2022

Personalis Reports Fourth Quarter and Full Year 2021 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Recent Highlights Reported quarterly revenue of $20.7 million in the fourth quarter of 2021 compared with $20.2 million in the fourth quarter of 2020, a 3% increase Revenue from biopharma and other customers, excluding the VA MVP (as defined below), of $15.4 mi

Business Wire | February 24, 2022

Personalis GAAP EPS of -$0.45 beats by $0.05, revenue of $20.68M in-line

Personalis press release (PSNL): Q4 GAAP EPS of -$0.45 beats by $0.05.Revenue of $20.68M (+2.5% Y/Y) in-line.Full year 2022 OutlookTotal company revenue is expected to be…

Seeking Alpha | February 24, 2022

Personalis to Present at the Cowen 42nd Annual Health Care Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 2:10 p.m. Eastern Time. About Personalis Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving

Business Wire | February 23, 2022

Read More 'PSNL' Stories Here

PSNL Price Returns

1-mo -20.76%
3-mo -55.45%
6-mo -66.64%
1-year -79.64%
3-year N/A
5-year N/A
YTD -67.90%
2021 -61.02%
2020 235.87%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4126 seconds.